HC Wainwright Issues Pessimistic Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.16 for the quarter, down from their previous forecast of $0.55. HC Wainwright currently has a “Buy” rating and a $115.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.57 EPS, FY2025 earnings at $1.93 EPS, FY2026 earnings at $3.80 EPS, FY2027 earnings at $6.26 EPS and FY2028 earnings at $7.34 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $181.89 million during the quarter, compared to analyst estimates of $200.12 million.

Other equities analysts have also issued reports about the company. Piper Sandler lifted their price objective on Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research note on Thursday. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.75.

Corcept Therapeutics Stock Performance

Shares of CORT opened at $60.58 on Monday. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $75.00. The company’s 50 day simple moving average is $59.96 and its 200 day simple moving average is $51.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The company has a market capitalization of $6.35 billion, a price-to-earnings ratio of 48.08 and a beta of 0.58.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank bought a new stake in Corcept Therapeutics during the 4th quarter valued at $42,055,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock valued at $56,637,000 after purchasing an additional 352,947 shares during the period. Braun Stacey Associates Inc. bought a new stake in shares of Corcept Therapeutics during the fourth quarter valued at about $14,935,000. FMR LLC lifted its holdings in Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after purchasing an additional 269,074 shares during the period. Finally, Synergy Asset Management LLC grew its position in Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after buying an additional 262,503 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The disclosure for this sale can be found here. Insiders have sold 26,600 shares of company stock valued at $1,399,576 over the last quarter. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.